Merck KGaA (ETR:MRK)
Germany flag Germany · Delayed Price · Currency is EUR
115.50
+0.25 (0.22%)
May 30, 2025, 5:41 PM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2012 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 2012 - 2020
Life Science
8.99B
Log In
Log In
Log In
Log In
Upgrade
Life Science Growth
0.59%
Log In
Log In
Log In
Log In
Upgrade
Healthcare
8.52B
Log In
Log In
Log In
Log In
Upgrade
Healthcare Growth
3.97%
Log In
Log In
Log In
Log In
Upgrade
Electronics
3.81B
Log In
Log In
Log In
Log In
Upgrade
Electronics Growth
3.21%
Log In
Log In
Log In
Log In
Upgrade
Oncology
2.00B
Log In
Log In
Log In
Log In
Upgrade
Oncology Growth
6.05%
Log In
Log In
Log In
Log In
Upgrade
Neurology & Immunology
1.68B
Log In
Log In
Log In
Log In
Upgrade
Neurology & Immunology Growth
-1.00%
Log In
Log In
Log In
Log In
Upgrade
Fertility
1.53B
Log In
Log In
Log In
Log In
Upgrade
Fertility Growth
-2.33%
Log In
Log In
Log In
Log In
Upgrade
Display Solutions
759.20M
Log In
Log In
Log In
Log In
Upgrade
Display Solutions Growth
-1.34%
Log In
Log In
Log In
Log In
Upgrade
Surface Solutions
398.90M
Log In
Log In
Log In
Log In
Upgrade
Surface Solutions Growth
-2.83%
Log In
Log In
Log In
Log In
Upgrade
Semiconductor Solutions
2.65B
Log In
Log In
Log In
Log In
Upgrade
Semiconductor Solutions Growth
5.59%
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular, Metabolism and Endocrinology
3.02B
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular, Metabolism and Endocrinology Growth
7.81%
Log In
Log In
Log In
Log In
Upgrade
Other Healthcare
300.60M
Log In
Log In
Log In
Log In
Upgrade
Other Healthcare Growth
18.35%
Log In
Log In
Log In
Log In
Upgrade
Process Solutions
3.62B
Log In
Log In
Log In
Log In
Upgrade
Process Solutions Growth
1.31%
Log In
Log In
Log In
Log In
Upgrade
Life Science Services
715.60M
Log In
Log In
Log In
Log In
Upgrade
Life Science Services Growth
-5.93%
Log In
Log In
Log In
Log In
Upgrade
Science & Lab Solutions
4.65B
Log In
Log In
Log In
Log In
Upgrade
Science & Lab Solutions Growth
1.11%
Log In
Log In
Log In
Log In
Upgrade

EBITDA by Product

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2012 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 2012 - 2020
Life Science EBITDA
2.60B
Log In
Log In
Log In
Log In
Upgrade
Life Science EBITDA Growth
2.77%
Log In
Log In
Log In
Log In
Upgrade
Healthcare EBITDA
3.08B
Log In
Log In
Log In
Log In
Upgrade
Healthcare EBITDA Growth
15.82%
Log In
Log In
Log In
Log In
Upgrade
Electronics EBITDA
977.30M
Log In
Log In
Log In
Log In
Upgrade
Electronics EBITDA Growth
7.14%
Log In
Log In
Log In
Log In
Upgrade
Corporate/Others EBITDA
-507.10M
Log In
Log In
Log In
Log In
Upgrade
Corporate/Others EBITDA Growth
41.65%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2012 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 2012 - 2020
Europe
6.26B
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
4.84%
Log In
Log In
Log In
Log In
Upgrade
North America
5.69B
Log In
Log In
Log In
Log In
Upgrade
North America Growth
-2.24%
Log In
Log In
Log In
Log In
Upgrade
Asia Pacific
7.09B
Log In
Log In
Log In
Log In
Upgrade
Asia Pacific Growth
2.55%
Log In
Log In
Log In
Log In
Upgrade
Latin America
1.46B
Log In
Log In
Log In
Log In
Upgrade
Latin America Growth
7.73%
Log In
Log In
Log In
Log In
Upgrade
Middle East & Africa
817.00M
Log In
Log In
Log In
Log In
Upgrade
Middle East & Africa Growth
7.44%
Log In
Log In
Log In
Log In
Upgrade